Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Do direct acting antivirals cure chronic hepatitis C?

We were dismayed that the Editors of the BMJ presented the widely discredited Cochrane review of Hepatitis C virus therapy as mainstream opinion. It is not... There is no credible explanation for the fall in hepatitis C liver disease morbidity and mortality associated with the introduction of effective anti-virals other than the use of these drugs.

Published
18 May 2018
From
BMJ
How states could be saving more hepatitis C patients

USC’s Neeraj Sood and colleagues propose an approach that leverages competition among drug manufacturers, saving states money and ensuring that more people get treatment

Published
15 May 2018
From
USC News
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents

Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need.

Published
14 May 2018
From
Intellectual Property Watch
Gilead Topples As Its Hepatitis C Drug Franchise Continues To Crumble

Sales of hepatitis C drugs Harvoni, Sovaldi and Epclusa raked in $1.05 billion, declining 59%. That was the single biggest year-over-year decline in the eight quarters since Gilead started reporting sales of hepatitis C drugs separately from its other antiviral products.

Published
02 May 2018
From
Investor's Business Daily
Many European countries are not ready to stop viral hepatitis

Many European countries lack a comprehensive policy to eliminate viral hepatitis as a major public health threat, according to a patient group-based survey implemented in 25 countries. The Hep-CORE study was coordinated by ISGlobal - an institution supported by the "la Caixa" Foundation - and led by the European Liver Patient's Association.

Published
19 April 2018
From
Eurekalert Medicine & Health
Linkage to care specialist facilitates access to hepatitis C treatment for people who inject drugs

A longitudinal study involving more than 1,000 individuals reports promising role for linkage to care specialists in expanding access to hepatitis C treatment for people who inject drugs. Almost 50% of patients referred to a medical practitioner made it to their first appointment and that 60% of those seen were initiated on treatment.

Published
13 April 2018
From
Eurekalert Inf Dis
How Well Do Docs Manage Potential Conflicts Between Hep C and HIV Meds?

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

Published
10 April 2018
From
Poz
Newly Discovered HCV Subtype is Resistant to Antiviral Treatment

A newly discovered hepatitis C virus (HCV) genotype 1 subtype harbors multiple resistance-associated mutations that combine to block therapeutic effect of NS5A inhibitor direct-acting antivirals (DAAs).

Published
21 March 2018
From
MD Magazine
Study: Shorter hepatitis C treatment effective in black patients

An eight-week treatment regimen for hepatitis C is just as effective as the recommended 12 weeks in African-American patients, according to a Harvard study.

Published
16 March 2018
From
UPI.com
The VA Will Eliminate Hepatitis C In Veterans By Year-end

At the 24th Annual Wharton Health Care Business Conference, Dr. David J. Shulkin, the Secretary of the U.S. Department of Veterans Affairs, announced that the VA was on track to eliminate hepatits C infections in the next 12 months for those who are willing and able to be treated. In October 2014, the VA had over 146,000 veterans afflicted with hepatitis C. By next October, this number will be only 20,000.

Published
02 March 2018
From
Forbes
← First12345...70Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.